alectinib Cancer Clinical Trials

Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study

104 sites for NCT04589845

AKT1 Mutation, +39 more biomarkers

Malignant Solid Tumor

ado-trastuzumab emtansine, +8 more drugs

immunotherapy, +1 more type

A Study to Evaluate Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)

155 sites for NCT03178552

ALK Alternative Transcription Site, +7 more biomarkers

Non-Small Cell Lung Carcinoma

alectinib, +2 more drugs

immunotherapy, +1 more type

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Patients With ALK Fusion-Positive Solid or CNS Tumors

11 sites for NCT04774718

ALK Fusion

Malignant Solid Tumor

alectinib

targeted therapy

A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response

48 sites for NCT04632992

AKT1 Mutation, +17 more biomarkers

Malignant Solid Tumor

ado-trastuzumab emtansine, +11 more drugs

chemotherapy, +2 more types

Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)

40 sites for NCT03944772

EGFR A763_Y764insFQEA, +7 more biomarkers

Large Cell Lung Neuroendocrine Carcinoma, +2 more conditions

alectinib, +11 more drugs

chemotherapy, +2 more types

A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors

24 sites for NCT04644315

ALK Amplification, +2 more biomarkers

Malignant Solid Tumor

alectinib

targeted therapy

The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy

35 sites for NCT04591431

AKT1 Amplification, +59 more biomarkers

Malignant Solid Tumor

ado-trastuzumab emtansine, +19 more drugs

immunotherapy, +1 more type

CRAFT: The NCT-PMO-1602 Phase II Trial

4 sites for NCT04551521

AKT1 Amplification, +78 more biomarkers

Malignant Solid Tumor

alectinib, +6 more drugs

immunotherapy, +1 more type

A Study of Alectinib, Entrectinib, Vemurafenib Plus Cobimetinib, or Pralsetinib in Patients With Resectable Stages II-III Non-Small Cell Lung Cancer With ALK, ROS1, NTRK, BRAF V600, or RET Molecular Alterations

20 sites for NCT04302025

ALK Fusion, +7 more biomarkers

Non-Small Cell Lung Carcinoma

alectinib, +8 more drugs

chemotherapy, +4 more types

Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity

1 site for NCT02314481

ALK Fusion, +4 more biomarkers

Non-Small Cell Lung Carcinoma, +2 more conditions

ado-trastuzumab emtansine, +7 more drugs

chemotherapy, +2 more types

Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer